With the Federal Reserve chatter quiet for at least the time being, after this week’s announcement of no increase in interest rates, investors need to refocus on the top stock calls that may make sense in aggressive growth portfolios as we get ready to start the fourth quarter soon. In what has been a very difficult market to trade this year, adding growth companies with a positive investment thesis makes good sense now.

A new research report from Cowen has focus call stocks to buy that seem to blend well with the current thesis the analysts have. Three of the companies would be very good additions to aggressive growth portfolios. All are related Outperform at Cowen.

American Eagle Outfitters

This top retail stock had acted good all year and earnings have been solid, but the stock still got hit hard in August. American Eagle Outfitters Inc. (NYSE: AEO) is a leading global specialty retailer offering high-quality, on-trend clothing, accessories and personal care products at affordable prices under its American Eagle Outfitters and Aerie brands. The company operates more than 1,000 stores in the United States, Canada, Mexico, China, Hong Kong and the United Kingdom, and ships to 81 countries worldwide through its websites. American Eagle Outfitters and Aerie merchandise also is available at 119 international stores operated by licensees in 18 countries.

Investors were cheered and the stock rallied as news that Jay Schottenstein, who serves as the executive chairman and interim CEO reported buying 500,000 shares at a weighted average price of $15.74 per share. He has been consistently buying shares over the past year.

ALSO READ: 4 Safe High-Yield Dividend Stocks to Buy for Ongoing Volatility

After a meeting in London with management, Cowen highlighted the clothing segment’s best denim execution and on-trend fashion. They think those positives could drive traffic upside, as well as long-term drivers of international, Aerie, digital and omni inventory. Good execution, solid inventory control and the recent pullback in the stock are all bullish items as well.

American Eagle investors are paid a solid 3.05% dividend. The Cowen price target for the stock is $20, and the Thomson/First Call consensus target is $19.13. Shares closed most recently at $16.26.
Boeing

This top aerospace industrial has sold off recently, offering investors a very solid entry point. Boeing Co. (NYSE: BA) has been on a downward trend since late February and may be ready to perk up. The company and its subsidiaries design, develop, manufacture, sell, service and support commercial jetliners, military aircraft, satellites, missile defense, human space flight and launch systems and services worldwide.

Cowen met with top management and has increased confidence in continuing good demand, 787 execution is good as the company works through the backlog, and cash flow looks to be strong with 787 deliveries and C-17 orders. The analysts also point to low oil prices as a bullish indicator for the top carriers that are Boeing’s big customers.

Boeing investors are paid a solid 2.63% dividend. The Cowen price target is $175, and the consensus target is $164. The shares closed trading on Thursday at $137.45.

ALSO READ: 4 Cheap Large-Cap Tech Stocks to Buy for Solid Gains

Shire

This is one of the Cowen top picks in specialty pharmaceuticals. Shire PLC (NASDAQ: SHPG) develops, licenses, manufactures, markets, distributes and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), and it also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology and gastrointestinal disorders, as well as early development projects primarily on rare diseases.

The Cowen analysts view the rather mixed market reaction to the Baxalta bid, and the market correction, as providing investors a compelling opportunity to refocus on the company’s true intrinsic value. Shire publicly placed its bid for Baxalta on August 4, offering 0.1687 of its American depositary shares for each Baxalta share, valuing them at $45.23 apiece. The offer represented a premium of 30% over the company’s stock price then. Baxalta initially said the bid was to low and recent reports indicate Shire is looking to sweeten the offer.

The Baxalta acquisition could produce $13 billion in revenues for Shire’s rare disease portfolio by 2020, according Bloomberg Intelligence analysis. Sales at the combined entity are projected to reach $20 billion. Cowen thinks that upcoming Lifitegrast PDUFA on October 25, which was granted a priority review by the FDA, is an important catalyst for Shire on a standalone basis and for the Baxalta bid prospects.

The Cowen price target of $325 is well above the $283.91 consensus target. The stock closed at $223.39.

ALSO READ: UBS Says Huge Oil Merger Should Go Through: 3 Big Stocks to Buy

While these companies are not suitable for all investors’ portfolios, they have outstanding upside potential and far less downside than high-flying momentum stocks.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.